|
Product name
|
Liraglutide
|
|
Sequence
|
H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-
Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]-
-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
|
|
CAS No.
|
204656-20-2
|
|
Molecular Formula
|
C172H265N43O51
|
|
Molecular Weight
|
3751.20
|
|
Storage
|
2~8℃
|
|
Appearance
|
White to
off-white crystalline powder
|
|
Test
|
Specification
|
Results
|
|
Appearance:
|
White to
off-white crystalline powder or lumps
|
White powder
|
|
Identity:
|
3751.2±1.0
|
3751.1
|
|
Purity (By
HPLC) :
|
Not Less than
98.0%;
|
99.51%
|
|
Residual
solvents:
|
≤0.25%total;
≤0.1%individual;
≤0.01%CH2CN
|
Complies
|
|
Related
Peptide
|
Total Impurity
≤ 2.0%
Largest Single
Impurity ≤ 1.0%
|
TI =0.41%
LSI =0.25%
|
|
Peptide
Content:
|
Not Less than
85.0%
|
87.7%
|
|
Water (K.F.):
|
Not more than
5%
|
4.2%
|
|
Acetate acid:
|
Not more than
10%
|
8.1%
|
|
Bacterial
Endotoxins
|
Not more than
50IU/mg
|
Complies
|
Function and Usage of Liraglutide 204656-20-2
1、 Type 2 diabetes
Liraglutide improves control of
blood glucose.It reduces meal-related hyperglycemia (for 24 hours after
administration) by increasing insulin secretion (only) when required by
increasing glucose levels, delaying gastric emptying, and suppressing prandial
glucagon secretion.
In common to various degrees with other GLP-1 receptor agonists, liraglutide
has advantages over more traditional therapies for type 2 diabetes:
· Liraglutide acts in a glucose-dependent manner,
meaning it will stimulate insulin secretion only when blood glucose levels are
higher than normal, preventing "overshoot". Consequently, it shows
negligible risk of hypoglycemia.
· Liraglutide has the potential for inhibiting
apoptosis and stimulating regeneration of beta cells (seen in animal studies).
· Liraglutide decreases appetite and inhibits body
weight gain, as shown in a head-to-head study versus glimepiride.
· Liraglutide lowers blood triglyceride levels.
2、Obesity
Liraglutide has been approved as an
injectable adjunct to a reduced-calorie diet and increased physical activity
for chronic weight management in adult patients. The specified criteria are an
initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or
greater (overweight), in the presence of at least one weight-related comorbid
condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In
late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial,
which is a randomised, double-blind, placebo-controlled, multinational trial in
non-diabetic people with obesity and non-diabetic people who are overweight
with comorbidities. In this phase 3a trial, there were 3,731 participants
randomised to treatment with liraglutide 3 mg or placebo, both in combination
with diet and exercise. Those who completed the 56-week trial achieved an
average weight loss of 9.2%, to be compared with a 3.5% reduction in the
placebo group.
